Transfer factor II: results of therapy.
Transfer factor is a dialyzable extract of sensitized leukocytes, which transfers reactivity from skin test-positive donors to skin test-negative recipients. Transfer factor supplied by our laboratory has been used therapeutically to induce cellular immunity in 78 patients around the world. Many patients received multiple doses of transfer factor ranging from 1 unit given every 6 months for 3 years to 1 unit every week for 6 months to as much as 8 units per week for a brief period. A total of 299 units of transfer factor have been given. Diseases in which transfer factor appeared to cause improvement include the Wiskott-Aldrich syndrome, severe combined immunodeficiency disease, mucocutaneous candidiasis, chronic active hepatitis, coccidioidmycosis, dysgammaglobulinemia, Behcet disease, aphthous stomatitis, linear morphea, familial keratoacanthoma and malignancy.
D000666:Amphotericin B / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000628:therapy; D001666:Binding Sites, Antibody; D002179:Candidiasis, Cutaneous / Q000628:therapy; D003047:Coccidioidomycosis / Q000628:therapy; D004406:Dysgammaglobulinemia / Q000628:therapy; D006505:Hepatitis / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000628:therapy*; D007167:Immunotherapy; D007636:Keratoacanthoma / Q000628:therapy; D008263:Macrophage Migration-Inhibitory Factors / Q000096:biosynthesis; D009000:Monocytes / Q000276:immunology; D009369:Neoplasms / Q000628:therapy; D012594:Scleroderma, Localized / Q000628:therapy; D013281:Stomatitis, Aphthous / Q000628:therapy; D014165:Transfer Factor / Q000627:therapeutic use*; D014923:Wiskott-Aldrich Syndrome / Q000628:therapy
D008263:Macrophage Migration-Inhibitory Factors; D014165:Transfer Factor; D000666:Amphotericin B